Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Kyle Binder

Neurology Fort Myers, FL Medical Doctor

NPI 1841635422 CMS profile 8801031

11215 Metro Pkwy Ste 1, Fort Myers, FL 33966

Open in the dashboard

General payments

$5,763

340 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kyle Binder of Fort Myers, FL is reported in the CMS Open Payments database as having received $5,763 across 340 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29 1
2024 General $89 4
2023 General $1,305 67
2022 General $2,438 145
2021 General $1,590 109
2020 General $313 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kyle Binder
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Kyle Binder were reported at $29. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Kyle Binder Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $313 $367 $82–$2,309 $114
2021 $1,590 $438 $104–$2,547 $132
2022 $2,438 $442 $103–$2,388 $149
2023 $1,305 $464 $119–$2,312 $160
2024 $89 $468 $119–$2,323 $164
2025 $29 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $1,165 82 payments
  2. Lilly USA, LLC $411 32 payments
  3. Biogen, Inc. $284 15 payments
  4. Teva Pharmaceuticals USA, Inc. $244 13 payments
  5. Celgene Corporation $240 17 payments
  6. Novartis Pharmaceuticals Corporation $236 27 payments
  7. Genzyme Corporation $220 11 payments
  8. Eisai Inc. $200 10 payments
  9. Alexion Pharmaceuticals, Inc. $195 8 payments
  10. Janssen Pharmaceuticals, Inc $188 9 payments
  11. Other $2,380 116 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $5,763 340 payments
Products named General payments · program years 2020–2025
  1. UBRELVY $721 53 payments
  2. EMGALITY $335 28 payments
  3. REYVOW $335 28 payments
  4. ZEPOSIA $248 17 payments
  5. QULIPTA $232 17 payments
  6. VUMERITY $221 11 payments
  7. AUBAGIO $220 11 payments
  8. AUSTEDO $197 11 payments
  9. KESIMPTA $191 24 payments
  10. MAYZENT $191 24 payments
  11. Other $3,503 178 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Neurology: 833

Drug cost

$272

Median for Neurology: $202,670

Branded share of claims

100%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 16 $272

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$27,633

Medicare's payments for the services billed

Medicare patients

261

Average age 76

Services billed

312

138 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 49%
Ischemic heart disease 49%
Chronic kidney disease 48%
Depression 41%
Heart failure 38%
Atrial fibrillation 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

340 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record